Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $219000.0.

  • Ligand Pharmaceuticals' Gains from Investment Securities rose 7520.0% to $219000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year increase of 24945.91%. This contributed to the annual value of $5.1 million for FY2024, which is 1295.36% up from last year.
  • Ligand Pharmaceuticals' Gains from Investment Securities amounted to $219000.0 in Q3 2025, which was up 7520.0% from $145000.0 recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Gains from Investment Securities peaked at $11.0 million during Q3 2023, and registered a low of -$10.7 million during Q4 2023.
  • In the last 5 years, Ligand Pharmaceuticals' Gains from Investment Securities had a median value of $2.1 million in 2022 and averaged $2.3 million.
  • Within the past 5 years, the most significant YoY rise in Ligand Pharmaceuticals' Gains from Investment Securities was 1140833.33% (2023), while the steepest drop was 58187.56% (2023).
  • Ligand Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $3.3 million in 2021, then crashed by 32.52% to $2.2 million in 2022, then crashed by 581.88% to -$10.7 million in 2023, then soared by 118.1% to $1.9 million in 2024, then crashed by 88.68% to $219000.0 in 2025.
  • Its last three reported values are $219000.0 in Q3 2025, $145000.0 for Q2 2025, and $8.9 million during Q1 2025.